Table 1 Baseline characteristics of 340 HIV positive adults by antiretroviral treatment initiated1
Tenofovir based regimen (n = 279) | Non tenofovir-based regimen (n = 60) | P | |
|---|---|---|---|
Age, years | < 0.001 | ||
18–25 | 50 (17.9) | 22 (36.7) | |
26–35 | 134 (48.0) | 31 (51.7) | |
36–45 | 66 (23.7) | 6 (10.0) | |
> 45 | 29 (10.4) | 1 (1.7) | |
Sex | 0.003 | ||
Males | 101 (36.2) | 10 (16.7) | |
Females | 178 (63.8) | 50 (83.3) | |
WHO Stage | 0.78 | ||
I | 84 (30.1) | 15 (25.0) | |
II | 82 (29.4) | 19 (31.7) | |
III | 89 (31.9) | 22 (36.7) | |
IV | 24 (8.6) | 4 (6.7) | |
Weight, kg | 49.2 (44.1; 54.3) | 47.3 (42.1; 51.3) | 0.08 |
Fat Free mass, Kg | 39.0 (35.2; 44.8) | 37.1 (33.7; 40.1) | 0.01 |
Fat mass, kg | 8.4 (6.0; 11.9) | 9.9 (7.2; 11.6) | 0.49 |
Height, m | 1.60 (1.54; 1.67) | 1.6 (1.5; 1.6) | 0.02 |
Body mass index, kg/m2 | 18.9 (17.4; 20.6) | 18.3 (17.2; 20.5) | 0.78 |
On tuberculosis treatment, Yes | 30 (10.8) | 5 (8.3) | 0.58 |
C-reactive protein, mg/L | 2.0 (0.6, 7.7) | 1.9 (0.4; 6.8) | 0.57 |
CD4 count, cells/ul | 178 (111; 243) | 192 (122; 231) | 0.45 |
Serum phosphate, mmol/La | 1.3 (0.3)) | 1.3 (0.3)) | 0.89 |
Hepatitis B surface antigen positive2, Yes | 10 (3.7) | 2 (3.6) | 0.97 |
Viral load, log (copies+ 1/mL) | 4.8 (4.3; 5.4) | 4.8 (4.3; 5.2) | 0.79 |
Urine Protein dipstick positive3, Yes | 14 (2.3) | 1 (6.6) | 0.28 |
eGFR, ml/min/1.73m2 a | 117.7 (21.7) | 122 (18.0) | 0.13 |